Early stoppage of empirical antibiotic therapy in paediatric acute leukaemia with high-risk febrile neutropenia: a randomized, open-label, phase 3, non-inferiority trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 41245542.
- Also identified by DOI 10.1016/j.eclinm.2025.103610 and PMC identifier 12612994.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Empirical antibiotic therapy (EAT) is commonly continued until recovery of neutrophil counts in paediatric acute leukaemia with high-risk febrile neutropenia. This study assessed whether early discontinuation of EAT was non-inferior to the continuation of EAT until absolute neutrophil count (ANC) ≥500/μL among children with high-risk febrile neutropenia. This open-label, phase 3, non-inferiority, randomized trial was conducted between October 2018 and August 2024 and enrolled children aged 2-18 years with acute leukaemia experiencing high-risk febrile neutropenia during induction chemotherapy. Patients clinically stable and afebrile for ≥72 h on EAT, with ANC <500/μL and no documented infection, were randomized to either stop EAT or continue it until ANC ≥500/μL. The primary outcome was proportion of fever recurrence, with a non-inferiority margin of 15 percentage points. Secondary outcomes included antibiotic duration, hospital readmissions, use of third-line antibiotics, use of therapeutic antifungals, and mortality. This study is registered at Clinical Trial Registry of India (CTRI/2018/015994). Of 280 patients randomized, 278 were analysed (140 stop arm, 138 continuation arm). Median age (IQR) was 8 (5-14) years, with 34.2% being female. Fever recurrence occurred in 52.1% (73/170) and 47.1% (65/138) children in stop and continuation arms respectively. The difference in fever recurrence between the arms was 5.0 percentage points (90% CI: -4.8 to 14.8 percentage points), establishing non-inferiority of the stop arm. The median (IQR) days of EAT after randomization were shorter in the stop arm [4.2 (0-10) vs 11 (7.2-15); p < 0.0001]. Mortality, hospital readmission, third-line antibiotic use, or therapeutic antifungal use did not differ between the two arms. Early discontinuation of EAT in paediatric acute leukaemia with high-risk febrile neutropenia was non-inferior to continuation of EAT until recovery of ANC. None.